Free Republic

A study reveals that the use of doxycycline may help protect against Clostridioides difficile (C. diff) infection for some patients with pneumonia. Specifically, study authors found that for hospitalized patients with community-acquired pneumonia who had experienced C. diff infections in the prior year, the use of doxycycline, instead of the more commonly used azithromycin, reduced the development of new C. diff infections by 45%. More than a third of patients who suffer a C. diff infection will go on to have another in the future. For patients who are admitted to a hospital with pneumonia, clinical guidelines typically recommend the...

Three weeks of oral azithromycin seems to be equivalent to six weeks of doxycycline for treatment of severe meibomian gland dysfunction (MGD), according to a study. Phit Upaphong, M.D. and colleagues conducted a randomized trial involving patients with moderate-to-severe MGD who were randomly assigned to receive oral azithromycin (1 g once per week for three weeks) or oral doxycycline (200 mg daily for six weeks). Overall, 137 eyes from 137 patients were randomly assigned to the azithromycin and doxycycline groups (68 and 69 eyes, respectively). The researchers found that the adjusted mean between-group difference of total MGD scores was −0.33...

Azithromycin helps improve asthma control and reduce exacerbations in children with poorly controlled asthma, according to a study published in the June issue of Chest. Jagat Jeevan Ghimire, M.D., from All India Institute of Medical Sciences in New Delhi, and colleagues randomly assigned 120 children (5 to 15 years of age) with poorly controlled asthma to receive azithromycin three times weekly for three months along with standard treatment or standard treatment alone. The researchers found that the numbers of children with well-controlled asthma according to Global Initiative for Asthma guidelines were 41 of 56 in the azithromycin group versus 10...

Last week, the World Tribune published an article revealing information that indicates the WHO likely knew ivermectin was effective for months, but blocked its use, all for Big Pharma. Dr. Andrew Hill, a senior visiting research fellow in pharmacology at Liverpool University, adviser to the Gates Foundation, and researcher for the WHO, was tasked with conducting an ivermectin trial for the WHO. Based on his preliminary findings, Hill testified enthusiastically about the use of ivermectin before the NIH COVID-19 Treatment Guidelines Panel on Jan. 6, 2021. But then he suddenly changed course and published a study dinging the drug’s efficacy...

At the start of the pandemic, researchers began testing existing antivirals in people hospitalized with severe Covid-19. But many of those trials failed to show any benefit from the antivirals. In hindsight, the choice to work in hospitals was a mistake. Scientists now know that the best time to try to block the coronavirus is in the first few days of the disease, when the virus is replicating rapidly and the immune system has not yet mounted a defense. In a trial of hospitalized patients, however, molnupiravir seemed to have no effect on the disease. In April, the companies announced...

Far-right activist Laura Loomer has described how she is in "so much pain" after contracting COVID-19, after previously hoping she would get the virus to prove its symptoms are "hyped up." Writing on messaging app Telegram, seen by Newsweek, Loomer said she got tested because she was suffering from fever, chills, nausea, runny nose, sore throat and aches that "made my whole body feel like I got hit by a bus." After confirming she had COVID, Loomer said that she is not vaccinated against the virus and is taking her own treatment consisting of "Azithromyacin and Hydroxychloroquine." She is also...

A new study has found that the use of weight-adjusted Hydroxychloroquine (HCQ) and Azithromycin (AZM) improved the survival of ventilated COVID-19 patients by nearly 200 percent. The observational study, which has not yet been peer-reviewed, was based on a re-analysis of 255 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic in the United States. The researchers found that, when the HCQ/AZM combination was given at lower dosages to treat ventilated COVID-19 patients, the risk of death was over three times higher. “We found that when the cumulative doses of two drugs, HCQ and AZM,...

Study detailsIn this study, based on a subset of critically ill COVID-19 patients, consisting of patients who required intubation and IMV, data from the medical records were analyzed using several novel methods. This included not only the vital signs and laboratory values but the therapeutic methods.The study was carried out on patients at Saint Barnabas Medical Center, New Jersey, with just over 1% having been clinically diagnosed to have COVID-19. Of the 255 patients, almost 80% died during the study period. Seven patients were transferred to another hospital on the ventilator, mostly after day 40 of hospitalization.Parameters were broadly comparable...

Objective: There is an urgent need for effective treatments to prevent or attenuate lung and systemic inflammation, endotheliitis, and thrombosis related to COVID-19. This study aimed to assess the effectiveness of a multidrug-therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid ("TNR4" therapy) to prevent hospitalization and death among ambulatory COVID19 cases in Tlaxcala, Mexico. Design and methods: A comparative effectiveness study was performed among 768 confirmed SARS-CoV2 cases aged 18–80 years, who received ambulatory care at the Ministry of Health of Tlaxcala. A total of 481 cases received the TNR4 therapy, while 287 received another treatment (comparison group). All...

Recently, a randomized controlled trial led out of the Rehman Medical College in Peshawar, Pakistan had some limitations and will probably be ignored by most of the main regulatory bodies. Nonetheless, the study offers some interesting data for investigating how to save lives during the pandemic. The researchers investigated Azithromycin versus Azithromycin and Ivermectin in 100 mild COVID-19 patients. Randomized 1:1, the investigators and study team measured symptom resolution. Both of the study groups also received tablets of paracetamol (Acetaminophen) at 500 mg if needed, Vitamin C at 500 mg once a day for 15 days, Zinc at 20 mg...

Early Outpatient Treatment: An Essential Part of a COVID-19 Solution Witnesses Peter A. McCullough, M.D., M.P.H. Vice Chief of Internal Medicine Baylor University Medical Center Download Testimony (143.9 KB) Harvey Risch, M.D., PH.D. Professor of Epidemiology Yale University Download Testimony (96.1 KB) George C. Fareed, M.D. Medical Director and Family Medicine Specialist Pioneers Medical Center Testimony-Fareed-2020-11-19 (155.1 KB) Ashish K. Jha, M.D., M.P.H. Dean of the School of Public Health Brown University Download Testimony (180.5 KB)

Any Predictions on when all of the MASK STUPIDNESS will be done?

If you're not promoting the accepted narrative, you don't get to express your views in the United States of America regardless of credentials. Original Story: Many of us, particularly conservatives, have had our perspectives censored by Big Tech, especially as it pertains to contentious issues like the coronavirus. Here at NOQ Report, we’ve had three posts taken down by Facebook, one on YouTube, and we’ve seen our status in Google’s search engine drop dramatically. But the truth is the truth so no matter how hard they try to bully us, we won’t back down. Breitbart and several front-line doctors experienced...

The French government on Wednesday revoked a decree authorising hospitals to prescribe the controversial drug for Covid-19 patients after France’s public health watchdog warned against its use to treat the disease. The drug has been the subject of much debate in France, where “maverick” Professor Didier Raoult claimed in March to have successfully treated Covid-19 patients using a combination of hydroxychloroquine and azithromycin. However, doctors have questioned the value of Professor Raoult’s study, saying it was poorly designed and based on too small a sample to offer hard evidence of benefit.

Brazil’s health minister resigned Friday after less than a month on the job in a sign of continuing upheaval over how the nation should battle the coronavirus pandemic, quitting a day after President Jair Bolsonaro stepped up pressure on him to expand use of the antimalarial drug chloroquine in treating patients. Dr. Nelson Teich, an oncologist and health care consultant, took the job April 17 faced with the task of aligning the ministry’s actions with the president’s view that Brazil’s economy must not be destroyed by restrictions to control spread of the virus. Teich’s predecessor, Luiz Henrique Mandetta, also had...

A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from COVID-19, the National Institutes of Health reports. The trial will enroll about 2,000 adults across the U.S. and study participants must have confirmed infection with SARS-CoV-2, the virus that causes COVID-19. They must also be experiencing fever, cough and/or shortness of breath. The investigators anticipate that many of those enrolled will be 60 years of age or older or have a comorbidity associated with developing serious complications from COVID-19, such as cardiovascular disease or diabetes. “We...

The 50,000 packages of Chloroquine, purchased from India by the pharmaceutical company Alvogen as a gift to the Icelandic nation for treating patients with COVID-19, arrived in Iceland yesterday, mbl.is reports. Landspítali National University Hospital will decide when to use the medication, which suffices to treat 25,000 patients. It was originally developed to fight malaria. A combination of Chloroquine or a related drug called Hydrochloroquine (Plaquenil) and the antibiotic Azithromycin (Zithromax) is already being used to fight COVID-19 in Iceland. In March, mbl.is reported that Alvogen had applied for permission to conduct a large clinical study of that combination of...

It's a youtube video, sorry. Dr. Vladimir Zelenko gives an update on the HCY "cocktail" It's Youtub, but worth the watch.

NEW YORK - Researchers at NYU's Grossman School of Medicine found patients given the antimalarial drug hydroxychloroquine along with zinc sulphate and the antibiotic azithromycin were 44 percent less likely to die from the coronavirus. "Certainly we have very limited options as far as what we have seen work for this infection so anything that may work is very exciting," said Dr. Joseph Rahimian, Infectious Disease Specialist at NYU Langone Health. (Please see full story at the link)

Despite the warnings around taking hydroxychloroquine to combat the symptoms of COVID-19, prescriptions in France have increased by as much as 7,000% in certain parts of the country since the pandemic began. As reported by La Provence, a study looking at the 466 million French prescriptions written since the pandemic began in France, show a huge spike in doctors prescribing the drug. In the last week of March, for instance, over 10,000 people were prescribed hydroxychloroquine in Marseille alone. In France and the U.S., the use of hydroxychloroquine has been fraught between those who think the risks are small enough...